Global GLP-1 Receptor Agonist Anti-obesity Drug Supply, Demand and Key Producers, 2026-2032
The global GLP-1 Receptor Agonist Anti-obesity Drug market size is expected to reach $ 71683 million by 2032, rising at a market growth of 18.2% CAGR during the forecast period (2026-2032).
GLP-1 receptor agonist anti-obesity drugs are prescription medicines that mimic or enhance glucagon-like peptide-1 activity to delay gastric emptying, increase satiety, reduce appetite and improve glucose metabolism, supporting long-term weight management in people with obesity or overweight with related risk factors. The category includes injectable products, oral formulations and long-acting modified dosage forms, with key evaluation metrics including weight-loss efficacy, durability, gastrointestinal tolerability, cardiometabolic benefit, dosing convenience and access. In 2025, global GLP-1 Receptor Agonist Anti-obesity Drugs production reached approximately 312 million unit.The average gross profit margin of this product is 80%.
The GLP-1 anti-obesity drug market is expanding rapidly amid rising obesity prevalence, stronger clinical evidence and higher patient willingness to pay. Originator companies are driving growth through capacity expansion, label expansion and improved dosing formats, while healthcare providers increasingly integrate pharmacological weight management into chronic disease care.
Competition is moving beyond weight-loss magnitude to durability, cardiovascular benefit, muscle-mass preservation, post-discontinuation rebound and affordability. Pen injectors remain the dominant format, while oral GLP-1 and longer-acting formulations may improve acceptance. However, manufacturing scale-up, cold chain requirements, supply shortages and pricing pressure remain major constraints.
Market growth is influenced by payer policy, reimbursement coverage, generic entry, online prescription compliance and drug safety monitoring. Future competition will center on differentiated clinical evidence, global capacity, supply-chain resilience and integrated chronic disease management services.
This report studies the global GLP-1 Receptor Agonist Anti-obesity Drug production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for GLP-1 Receptor Agonist Anti-obesity Drug and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of GLP-1 Receptor Agonist Anti-obesity Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global GLP-1 Receptor Agonist Anti-obesity Drug total production and demand, 2021-2032, (K Units)
Global GLP-1 Receptor Agonist Anti-obesity Drug total production value, 2021-2032, (USD Million)
Global GLP-1 Receptor Agonist Anti-obesity Drug production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global GLP-1 Receptor Agonist Anti-obesity Drug consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: GLP-1 Receptor Agonist Anti-obesity Drug domestic production, consumption, key domestic manufacturers and share
Global GLP-1 Receptor Agonist Anti-obesity Drug production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global GLP-1 Receptor Agonist Anti-obesity Drug production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global GLP-1 Receptor Agonist Anti-obesity Drug production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global GLP-1 Receptor Agonist Anti-obesity Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Eli Lilly, Huadong Medicine, Renhui Bio, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World GLP-1 Receptor Agonist Anti-obesity Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global GLP-1 Receptor Agonist Anti-obesity Drug Market, By Region:
1. How big is the global GLP-1 Receptor Agonist Anti-obesity Drug market?
2. What is the demand of the global GLP-1 Receptor Agonist Anti-obesity Drug market?
3. What is the year over year growth of the global GLP-1 Receptor Agonist Anti-obesity Drug market?
4. What is the production and production value of the global GLP-1 Receptor Agonist Anti-obesity Drug market?
5. Who are the key producers in the global GLP-1 Receptor Agonist Anti-obesity Drug market?
6. What are the growth factors driving the market demand?
GLP-1 receptor agonist anti-obesity drugs are prescription medicines that mimic or enhance glucagon-like peptide-1 activity to delay gastric emptying, increase satiety, reduce appetite and improve glucose metabolism, supporting long-term weight management in people with obesity or overweight with related risk factors. The category includes injectable products, oral formulations and long-acting modified dosage forms, with key evaluation metrics including weight-loss efficacy, durability, gastrointestinal tolerability, cardiometabolic benefit, dosing convenience and access. In 2025, global GLP-1 Receptor Agonist Anti-obesity Drugs production reached approximately 312 million unit.The average gross profit margin of this product is 80%.
The GLP-1 anti-obesity drug market is expanding rapidly amid rising obesity prevalence, stronger clinical evidence and higher patient willingness to pay. Originator companies are driving growth through capacity expansion, label expansion and improved dosing formats, while healthcare providers increasingly integrate pharmacological weight management into chronic disease care.
Competition is moving beyond weight-loss magnitude to durability, cardiovascular benefit, muscle-mass preservation, post-discontinuation rebound and affordability. Pen injectors remain the dominant format, while oral GLP-1 and longer-acting formulations may improve acceptance. However, manufacturing scale-up, cold chain requirements, supply shortages and pricing pressure remain major constraints.
Market growth is influenced by payer policy, reimbursement coverage, generic entry, online prescription compliance and drug safety monitoring. Future competition will center on differentiated clinical evidence, global capacity, supply-chain resilience and integrated chronic disease management services.
This report studies the global GLP-1 Receptor Agonist Anti-obesity Drug production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for GLP-1 Receptor Agonist Anti-obesity Drug and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of GLP-1 Receptor Agonist Anti-obesity Drug that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global GLP-1 Receptor Agonist Anti-obesity Drug total production and demand, 2021-2032, (K Units)
Global GLP-1 Receptor Agonist Anti-obesity Drug total production value, 2021-2032, (USD Million)
Global GLP-1 Receptor Agonist Anti-obesity Drug production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global GLP-1 Receptor Agonist Anti-obesity Drug consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: GLP-1 Receptor Agonist Anti-obesity Drug domestic production, consumption, key domestic manufacturers and share
Global GLP-1 Receptor Agonist Anti-obesity Drug production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global GLP-1 Receptor Agonist Anti-obesity Drug production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global GLP-1 Receptor Agonist Anti-obesity Drug production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global GLP-1 Receptor Agonist Anti-obesity Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Eli Lilly, Huadong Medicine, Renhui Bio, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World GLP-1 Receptor Agonist Anti-obesity Drug market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global GLP-1 Receptor Agonist Anti-obesity Drug Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Semaglutide
- Liraglutide
- Oral GLP-1 Agonist
- Long-acting GLP-1 Agonist
- Generic Or Biosimilar GLP-1
- Next-generation GLP-1
- Other
- Injectable
- Oral Tablet
- Pen Injector
- Vial Or Cartridge
- Implantable Or Depot
- Other
- Prescription Obesity Treatment
- Diabetes With Weight Management
- Cardiometabolic Risk Reduction
- Adolescent Obesity
- Other
- Hospital Pharmacies
- Retail Pharmacies
- Other
- Novo Nordisk
- Eli Lilly
- Huadong Medicine
- Renhui Bio
1. How big is the global GLP-1 Receptor Agonist Anti-obesity Drug market?
2. What is the demand of the global GLP-1 Receptor Agonist Anti-obesity Drug market?
3. What is the year over year growth of the global GLP-1 Receptor Agonist Anti-obesity Drug market?
4. What is the production and production value of the global GLP-1 Receptor Agonist Anti-obesity Drug market?
5. Who are the key producers in the global GLP-1 Receptor Agonist Anti-obesity Drug market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 GLP-1 Receptor Agonist Anti-obesity Drug Introduction
1.2 World GLP-1 Receptor Agonist Anti-obesity Drug Supply & Forecast
1.2.1 World GLP-1 Receptor Agonist Anti-obesity Drug Production Value (2021 & 2025 & 2032)
1.2.2 World GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032)
1.2.3 World GLP-1 Receptor Agonist Anti-obesity Drug Pricing Trends (2021-2032)
1.3 World GLP-1 Receptor Agonist Anti-obesity Drug Production by Region (Based on Production Site)
1.3.1 World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Region (2021-2032)
1.3.2 World GLP-1 Receptor Agonist Anti-obesity Drug Production by Region (2021-2032)
1.3.3 World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Region (2021-2032)
1.3.4 North America GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032)
1.3.5 Europe GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032)
1.3.6 China GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032)
1.3.7 Japan GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032)
1.3.8 India GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 GLP-1 Receptor Agonist Anti-obesity Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 GLP-1 Receptor Agonist Anti-obesity Drug Major Market Trends
2 DEMAND SUMMARY
2.1 World GLP-1 Receptor Agonist Anti-obesity Drug Demand (2021-2032)
2.2 World GLP-1 Receptor Agonist Anti-obesity Drug Consumption by Region
2.2.1 World GLP-1 Receptor Agonist Anti-obesity Drug Consumption by Region (2021-2026)
2.2.2 World GLP-1 Receptor Agonist Anti-obesity Drug Consumption Forecast by Region (2027-2032)
2.3 United States GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032)
2.4 China GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032)
2.5 Europe GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032)
2.6 Japan GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032)
2.7 South Korea GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032)
2.8 ASEAN GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032)
2.9 India GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Manufacturer (2021-2026)
3.2 World GLP-1 Receptor Agonist Anti-obesity Drug Production by Manufacturer (2021-2026)
3.3 World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Manufacturer (2021-2026)
3.4 GLP-1 Receptor Agonist Anti-obesity Drug Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for GLP-1 Receptor Agonist Anti-obesity Drug in 2025
3.5.3 Global Concentration Ratios (CR8) for GLP-1 Receptor Agonist Anti-obesity Drug in 2025
3.6 GLP-1 Receptor Agonist Anti-obesity Drug Market: Overall Company Footprint Analysis
3.6.1 GLP-1 Receptor Agonist Anti-obesity Drug Market: Region Footprint
3.6.2 GLP-1 Receptor Agonist Anti-obesity Drug Market: Company Product Type Footprint
3.6.3 GLP-1 Receptor Agonist Anti-obesity Drug Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Production Value Comparison
4.1.1 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Production Comparison
4.2.1 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Consumption Comparison
4.3.1 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers and Market Share, 2021-2026
4.4.1 United States Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value (2021-2026)
4.4.3 United States Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2026)
4.5 China Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers and Market Share
4.5.1 China Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value (2021-2026)
4.5.3 China Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2026)
4.6 Rest of World Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World GLP-1 Receptor Agonist Anti-obesity Drug Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Semaglutide
5.2.2 Liraglutide
5.2.3 Oral GLP-1 Agonist
5.2.4 Long-acting GLP-1 Agonist
5.2.5 Generic Or Biosimilar GLP-1
5.2.6 Next-generation GLP-1
5.2.7 Other
5.3 Market Segment by Type
5.3.1 World GLP-1 Receptor Agonist Anti-obesity Drug Production by Type (2021-2032)
5.3.2 World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Type (2021-2032)
5.3.3 World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY DOSAGE FORM
6.1 World GLP-1 Receptor Agonist Anti-obesity Drug Market Size Overview by Dosage Form: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Dosage Form
6.2.1 Injectable
6.2.2 Oral Tablet
6.2.3 Pen Injector
6.2.4 Vial Or Cartridge
6.2.5 Implantable Or Depot
6.2.6 Other
6.3 Market Segment by Dosage Form
6.3.1 World GLP-1 Receptor Agonist Anti-obesity Drug Production by Dosage Form (2021-2032)
6.3.2 World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Dosage Form (2021-2032)
6.3.3 World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Dosage Form (2021-2032)
7 MARKET ANALYSIS BY INDICATION
7.1 World GLP-1 Receptor Agonist Anti-obesity Drug Market Size Overview by Indication: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Indication
7.2.1 Prescription Obesity Treatment
7.2.2 Diabetes With Weight Management
7.2.3 Cardiometabolic Risk Reduction
7.2.4 Adolescent Obesity
7.2.5 Other
7.3 Market Segment by Indication
7.3.1 World GLP-1 Receptor Agonist Anti-obesity Drug Production by Indication (2021-2032)
7.3.2 World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Indication (2021-2032)
7.3.3 World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Indication (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World GLP-1 Receptor Agonist Anti-obesity Drug Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital Pharmacies
8.2.2 Retail Pharmacies
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World GLP-1 Receptor Agonist Anti-obesity Drug Production by Application (2021-2032)
8.3.2 World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Application (2021-2032)
8.3.3 World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Novo Nordisk
9.1.1 Novo Nordisk Details
9.1.2 Novo Nordisk Major Business
9.1.3 Novo Nordisk GLP-1 Receptor Agonist Anti-obesity Drug Product and Services
9.1.4 Novo Nordisk GLP-1 Receptor Agonist Anti-obesity Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Novo Nordisk Recent Developments/Updates
9.1.6 Novo Nordisk Competitive Strengths & Weaknesses
9.2 Eli Lilly
9.2.1 Eli Lilly Details
9.2.2 Eli Lilly Major Business
9.2.3 Eli Lilly GLP-1 Receptor Agonist Anti-obesity Drug Product and Services
9.2.4 Eli Lilly GLP-1 Receptor Agonist Anti-obesity Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Eli Lilly Recent Developments/Updates
9.2.6 Eli Lilly Competitive Strengths & Weaknesses
9.3 Huadong Medicine
9.3.1 Huadong Medicine Details
9.3.2 Huadong Medicine Major Business
9.3.3 Huadong Medicine GLP-1 Receptor Agonist Anti-obesity Drug Product and Services
9.3.4 Huadong Medicine GLP-1 Receptor Agonist Anti-obesity Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Huadong Medicine Recent Developments/Updates
9.3.6 Huadong Medicine Competitive Strengths & Weaknesses
9.4 Renhui Bio
9.4.1 Renhui Bio Details
9.4.2 Renhui Bio Major Business
9.4.3 Renhui Bio GLP-1 Receptor Agonist Anti-obesity Drug Product and Services
9.4.4 Renhui Bio GLP-1 Receptor Agonist Anti-obesity Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Renhui Bio Recent Developments/Updates
9.4.6 Renhui Bio Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 GLP-1 Receptor Agonist Anti-obesity Drug Industry Chain
10.2 GLP-1 Receptor Agonist Anti-obesity Drug Upstream Analysis
10.2.1 GLP-1 Receptor Agonist Anti-obesity Drug Core Raw Materials
10.2.2 Main Manufacturers of GLP-1 Receptor Agonist Anti-obesity Drug Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 GLP-1 Receptor Agonist Anti-obesity Drug Production Mode
10.6 GLP-1 Receptor Agonist Anti-obesity Drug Procurement Model
10.7 GLP-1 Receptor Agonist Anti-obesity Drug Industry Sales Model and Sales Channels
10.7.1 GLP-1 Receptor Agonist Anti-obesity Drug Sales Model
10.7.2 GLP-1 Receptor Agonist Anti-obesity Drug Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 GLP-1 Receptor Agonist Anti-obesity Drug Introduction
1.2 World GLP-1 Receptor Agonist Anti-obesity Drug Supply & Forecast
1.2.1 World GLP-1 Receptor Agonist Anti-obesity Drug Production Value (2021 & 2025 & 2032)
1.2.2 World GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032)
1.2.3 World GLP-1 Receptor Agonist Anti-obesity Drug Pricing Trends (2021-2032)
1.3 World GLP-1 Receptor Agonist Anti-obesity Drug Production by Region (Based on Production Site)
1.3.1 World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Region (2021-2032)
1.3.2 World GLP-1 Receptor Agonist Anti-obesity Drug Production by Region (2021-2032)
1.3.3 World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Region (2021-2032)
1.3.4 North America GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032)
1.3.5 Europe GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032)
1.3.6 China GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032)
1.3.7 Japan GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032)
1.3.8 India GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 GLP-1 Receptor Agonist Anti-obesity Drug Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 GLP-1 Receptor Agonist Anti-obesity Drug Major Market Trends
2 DEMAND SUMMARY
2.1 World GLP-1 Receptor Agonist Anti-obesity Drug Demand (2021-2032)
2.2 World GLP-1 Receptor Agonist Anti-obesity Drug Consumption by Region
2.2.1 World GLP-1 Receptor Agonist Anti-obesity Drug Consumption by Region (2021-2026)
2.2.2 World GLP-1 Receptor Agonist Anti-obesity Drug Consumption Forecast by Region (2027-2032)
2.3 United States GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032)
2.4 China GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032)
2.5 Europe GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032)
2.6 Japan GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032)
2.7 South Korea GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032)
2.8 ASEAN GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032)
2.9 India GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Manufacturer (2021-2026)
3.2 World GLP-1 Receptor Agonist Anti-obesity Drug Production by Manufacturer (2021-2026)
3.3 World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Manufacturer (2021-2026)
3.4 GLP-1 Receptor Agonist Anti-obesity Drug Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global GLP-1 Receptor Agonist Anti-obesity Drug Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for GLP-1 Receptor Agonist Anti-obesity Drug in 2025
3.5.3 Global Concentration Ratios (CR8) for GLP-1 Receptor Agonist Anti-obesity Drug in 2025
3.6 GLP-1 Receptor Agonist Anti-obesity Drug Market: Overall Company Footprint Analysis
3.6.1 GLP-1 Receptor Agonist Anti-obesity Drug Market: Region Footprint
3.6.2 GLP-1 Receptor Agonist Anti-obesity Drug Market: Company Product Type Footprint
3.6.3 GLP-1 Receptor Agonist Anti-obesity Drug Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Production Value Comparison
4.1.1 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Production Comparison
4.2.1 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Consumption Comparison
4.3.1 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers and Market Share, 2021-2026
4.4.1 United States Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value (2021-2026)
4.4.3 United States Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2026)
4.5 China Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers and Market Share
4.5.1 China Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value (2021-2026)
4.5.3 China Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2026)
4.6 Rest of World Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World GLP-1 Receptor Agonist Anti-obesity Drug Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Semaglutide
5.2.2 Liraglutide
5.2.3 Oral GLP-1 Agonist
5.2.4 Long-acting GLP-1 Agonist
5.2.5 Generic Or Biosimilar GLP-1
5.2.6 Next-generation GLP-1
5.2.7 Other
5.3 Market Segment by Type
5.3.1 World GLP-1 Receptor Agonist Anti-obesity Drug Production by Type (2021-2032)
5.3.2 World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Type (2021-2032)
5.3.3 World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY DOSAGE FORM
6.1 World GLP-1 Receptor Agonist Anti-obesity Drug Market Size Overview by Dosage Form: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Dosage Form
6.2.1 Injectable
6.2.2 Oral Tablet
6.2.3 Pen Injector
6.2.4 Vial Or Cartridge
6.2.5 Implantable Or Depot
6.2.6 Other
6.3 Market Segment by Dosage Form
6.3.1 World GLP-1 Receptor Agonist Anti-obesity Drug Production by Dosage Form (2021-2032)
6.3.2 World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Dosage Form (2021-2032)
6.3.3 World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Dosage Form (2021-2032)
7 MARKET ANALYSIS BY INDICATION
7.1 World GLP-1 Receptor Agonist Anti-obesity Drug Market Size Overview by Indication: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Indication
7.2.1 Prescription Obesity Treatment
7.2.2 Diabetes With Weight Management
7.2.3 Cardiometabolic Risk Reduction
7.2.4 Adolescent Obesity
7.2.5 Other
7.3 Market Segment by Indication
7.3.1 World GLP-1 Receptor Agonist Anti-obesity Drug Production by Indication (2021-2032)
7.3.2 World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Indication (2021-2032)
7.3.3 World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Indication (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World GLP-1 Receptor Agonist Anti-obesity Drug Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital Pharmacies
8.2.2 Retail Pharmacies
8.2.3 Other
8.3 Market Segment by Application
8.3.1 World GLP-1 Receptor Agonist Anti-obesity Drug Production by Application (2021-2032)
8.3.2 World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Application (2021-2032)
8.3.3 World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Novo Nordisk
9.1.1 Novo Nordisk Details
9.1.2 Novo Nordisk Major Business
9.1.3 Novo Nordisk GLP-1 Receptor Agonist Anti-obesity Drug Product and Services
9.1.4 Novo Nordisk GLP-1 Receptor Agonist Anti-obesity Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Novo Nordisk Recent Developments/Updates
9.1.6 Novo Nordisk Competitive Strengths & Weaknesses
9.2 Eli Lilly
9.2.1 Eli Lilly Details
9.2.2 Eli Lilly Major Business
9.2.3 Eli Lilly GLP-1 Receptor Agonist Anti-obesity Drug Product and Services
9.2.4 Eli Lilly GLP-1 Receptor Agonist Anti-obesity Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Eli Lilly Recent Developments/Updates
9.2.6 Eli Lilly Competitive Strengths & Weaknesses
9.3 Huadong Medicine
9.3.1 Huadong Medicine Details
9.3.2 Huadong Medicine Major Business
9.3.3 Huadong Medicine GLP-1 Receptor Agonist Anti-obesity Drug Product and Services
9.3.4 Huadong Medicine GLP-1 Receptor Agonist Anti-obesity Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Huadong Medicine Recent Developments/Updates
9.3.6 Huadong Medicine Competitive Strengths & Weaknesses
9.4 Renhui Bio
9.4.1 Renhui Bio Details
9.4.2 Renhui Bio Major Business
9.4.3 Renhui Bio GLP-1 Receptor Agonist Anti-obesity Drug Product and Services
9.4.4 Renhui Bio GLP-1 Receptor Agonist Anti-obesity Drug Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Renhui Bio Recent Developments/Updates
9.4.6 Renhui Bio Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 GLP-1 Receptor Agonist Anti-obesity Drug Industry Chain
10.2 GLP-1 Receptor Agonist Anti-obesity Drug Upstream Analysis
10.2.1 GLP-1 Receptor Agonist Anti-obesity Drug Core Raw Materials
10.2.2 Main Manufacturers of GLP-1 Receptor Agonist Anti-obesity Drug Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 GLP-1 Receptor Agonist Anti-obesity Drug Production Mode
10.6 GLP-1 Receptor Agonist Anti-obesity Drug Procurement Model
10.7 GLP-1 Receptor Agonist Anti-obesity Drug Industry Sales Model and Sales Channels
10.7.1 GLP-1 Receptor Agonist Anti-obesity Drug Sales Model
10.7.2 GLP-1 Receptor Agonist Anti-obesity Drug Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Region (2021-2026) & (USD Million)
Table 3. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Region (2027-2032) & (USD Million)
Table 4. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Region (2021-2026)
Table 5. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Region (2027-2032)
Table 6. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Region (2021-2026) & (K Units)
Table 7. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Region (2027-2032) & (K Units)
Table 8. World GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share by Region (2021-2026)
Table 9. World GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share by Region (2027-2032)
Table 10. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Region (2027-2032) & (US$/Unit)
Table 12. GLP-1 Receptor Agonist Anti-obesity Drug Major Market Trends
Table 13. World GLP-1 Receptor Agonist Anti-obesity Drug Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World GLP-1 Receptor Agonist Anti-obesity Drug Consumption by Region (2021-2026) & (K Units)
Table 15. World GLP-1 Receptor Agonist Anti-obesity Drug Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key GLP-1 Receptor Agonist Anti-obesity Drug Producers in 2025
Table 18. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key GLP-1 Receptor Agonist Anti-obesity Drug Producers in 2025
Table 20. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global GLP-1 Receptor Agonist Anti-obesity Drug Company Evaluation Quadrant
Table 22. World GLP-1 Receptor Agonist Anti-obesity Drug Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and GLP-1 Receptor Agonist Anti-obesity Drug Production Site of Key Manufacturer
Table 24. GLP-1 Receptor Agonist Anti-obesity Drug Market: Company Product Type Footprint
Table 25. GLP-1 Receptor Agonist Anti-obesity Drug Market: Company Product Application Footprint
Table 26. GLP-1 Receptor Agonist Anti-obesity Drug Competitive Factors
Table 27. GLP-1 Receptor Agonist Anti-obesity Drug New Entrant and Capacity Expansion Plans
Table 28. GLP-1 Receptor Agonist Anti-obesity Drug Mergers & Acquisitions Activity
Table 29. United States VS China GLP-1 Receptor Agonist Anti-obesity Drug Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China GLP-1 Receptor Agonist Anti-obesity Drug Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China GLP-1 Receptor Agonist Anti-obesity Drug Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share (2021-2026)
Table 37. China Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share (2021-2026)
Table 42. Rest of World Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share (2021-2026)
Table 47. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Type (2021-2026) & (K Units)
Table 49. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Type (2027-2032) & (K Units)
Table 50. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Type (2021-2026) & (USD Million)
Table 51. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Type (2027-2032) & (USD Million)
Table 52. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 55. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Dosage Form (2021-2026) & (K Units)
Table 56. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Dosage Form (2027-2032) & (K Units)
Table 57. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Dosage Form (2021-2026) & (USD Million)
Table 58. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Dosage Form (2027-2032) & (USD Million)
Table 59. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Dosage Form (2021-2026) & (US$/Unit)
Table 60. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Dosage Form (2027-2032) & (US$/Unit)
Table 61. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Indication, (USD Million), 2021 & 2025 & 2032
Table 62. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Indication (2021-2026) & (K Units)
Table 63. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Indication (2027-2032) & (K Units)
Table 64. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Indication (2021-2026) & (USD Million)
Table 65. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Indication (2027-2032) & (USD Million)
Table 66. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Indication (2021-2026) & (US$/Unit)
Table 67. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Indication (2027-2032) & (US$/Unit)
Table 68. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Application (2021-2026) & (K Units)
Table 70. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Application (2027-2032) & (K Units)
Table 71. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Application (2021-2026) & (USD Million)
Table 72. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Application (2027-2032) & (USD Million)
Table 73. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Application (2027-2032) & (US$/Unit)
Table 75. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 76. Novo Nordisk Major Business
Table 77. Novo Nordisk GLP-1 Receptor Agonist Anti-obesity Drug Product and Services
Table 78. Novo Nordisk GLP-1 Receptor Agonist Anti-obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Novo Nordisk Recent Developments/Updates
Table 80. Novo Nordisk Competitive Strengths & Weaknesses
Table 81. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 82. Eli Lilly Major Business
Table 83. Eli Lilly GLP-1 Receptor Agonist Anti-obesity Drug Product and Services
Table 84. Eli Lilly GLP-1 Receptor Agonist Anti-obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Eli Lilly Recent Developments/Updates
Table 86. Eli Lilly Competitive Strengths & Weaknesses
Table 87. Huadong Medicine Basic Information, Manufacturing Base and Competitors
Table 88. Huadong Medicine Major Business
Table 89. Huadong Medicine GLP-1 Receptor Agonist Anti-obesity Drug Product and Services
Table 90. Huadong Medicine GLP-1 Receptor Agonist Anti-obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Huadong Medicine Recent Developments/Updates
Table 92. Huadong Medicine Competitive Strengths & Weaknesses
Table 93. Renhui Bio Basic Information, Manufacturing Base and Competitors
Table 94. Renhui Bio Major Business
Table 95. Renhui Bio GLP-1 Receptor Agonist Anti-obesity Drug Product and Services
Table 96. Renhui Bio GLP-1 Receptor Agonist Anti-obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Renhui Bio Recent Developments/Updates
Table 98. Renhui Bio Competitive Strengths & Weaknesses
Table 99. Global Key Players of GLP-1 Receptor Agonist Anti-obesity Drug Upstream (Raw Materials)
Table 100. Global GLP-1 Receptor Agonist Anti-obesity Drug Typical Customers
Table 101. GLP-1 Receptor Agonist Anti-obesity Drug Typical Distributors
Table 1. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Region (2021-2026) & (USD Million)
Table 3. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Region (2027-2032) & (USD Million)
Table 4. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Region (2021-2026)
Table 5. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Region (2027-2032)
Table 6. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Region (2021-2026) & (K Units)
Table 7. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Region (2027-2032) & (K Units)
Table 8. World GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share by Region (2021-2026)
Table 9. World GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share by Region (2027-2032)
Table 10. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Region (2027-2032) & (US$/Unit)
Table 12. GLP-1 Receptor Agonist Anti-obesity Drug Major Market Trends
Table 13. World GLP-1 Receptor Agonist Anti-obesity Drug Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World GLP-1 Receptor Agonist Anti-obesity Drug Consumption by Region (2021-2026) & (K Units)
Table 15. World GLP-1 Receptor Agonist Anti-obesity Drug Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key GLP-1 Receptor Agonist Anti-obesity Drug Producers in 2025
Table 18. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key GLP-1 Receptor Agonist Anti-obesity Drug Producers in 2025
Table 20. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global GLP-1 Receptor Agonist Anti-obesity Drug Company Evaluation Quadrant
Table 22. World GLP-1 Receptor Agonist Anti-obesity Drug Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and GLP-1 Receptor Agonist Anti-obesity Drug Production Site of Key Manufacturer
Table 24. GLP-1 Receptor Agonist Anti-obesity Drug Market: Company Product Type Footprint
Table 25. GLP-1 Receptor Agonist Anti-obesity Drug Market: Company Product Application Footprint
Table 26. GLP-1 Receptor Agonist Anti-obesity Drug Competitive Factors
Table 27. GLP-1 Receptor Agonist Anti-obesity Drug New Entrant and Capacity Expansion Plans
Table 28. GLP-1 Receptor Agonist Anti-obesity Drug Mergers & Acquisitions Activity
Table 29. United States VS China GLP-1 Receptor Agonist Anti-obesity Drug Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China GLP-1 Receptor Agonist Anti-obesity Drug Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China GLP-1 Receptor Agonist Anti-obesity Drug Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share (2021-2026)
Table 37. China Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share (2021-2026)
Table 42. Rest of World Based GLP-1 Receptor Agonist Anti-obesity Drug Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share (2021-2026)
Table 47. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Type (2021-2026) & (K Units)
Table 49. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Type (2027-2032) & (K Units)
Table 50. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Type (2021-2026) & (USD Million)
Table 51. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Type (2027-2032) & (USD Million)
Table 52. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 55. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Dosage Form (2021-2026) & (K Units)
Table 56. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Dosage Form (2027-2032) & (K Units)
Table 57. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Dosage Form (2021-2026) & (USD Million)
Table 58. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Dosage Form (2027-2032) & (USD Million)
Table 59. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Dosage Form (2021-2026) & (US$/Unit)
Table 60. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Dosage Form (2027-2032) & (US$/Unit)
Table 61. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Indication, (USD Million), 2021 & 2025 & 2032
Table 62. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Indication (2021-2026) & (K Units)
Table 63. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Indication (2027-2032) & (K Units)
Table 64. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Indication (2021-2026) & (USD Million)
Table 65. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Indication (2027-2032) & (USD Million)
Table 66. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Indication (2021-2026) & (US$/Unit)
Table 67. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Indication (2027-2032) & (US$/Unit)
Table 68. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Application (2021-2026) & (K Units)
Table 70. World GLP-1 Receptor Agonist Anti-obesity Drug Production by Application (2027-2032) & (K Units)
Table 71. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Application (2021-2026) & (USD Million)
Table 72. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Application (2027-2032) & (USD Million)
Table 73. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Application (2027-2032) & (US$/Unit)
Table 75. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 76. Novo Nordisk Major Business
Table 77. Novo Nordisk GLP-1 Receptor Agonist Anti-obesity Drug Product and Services
Table 78. Novo Nordisk GLP-1 Receptor Agonist Anti-obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Novo Nordisk Recent Developments/Updates
Table 80. Novo Nordisk Competitive Strengths & Weaknesses
Table 81. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 82. Eli Lilly Major Business
Table 83. Eli Lilly GLP-1 Receptor Agonist Anti-obesity Drug Product and Services
Table 84. Eli Lilly GLP-1 Receptor Agonist Anti-obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Eli Lilly Recent Developments/Updates
Table 86. Eli Lilly Competitive Strengths & Weaknesses
Table 87. Huadong Medicine Basic Information, Manufacturing Base and Competitors
Table 88. Huadong Medicine Major Business
Table 89. Huadong Medicine GLP-1 Receptor Agonist Anti-obesity Drug Product and Services
Table 90. Huadong Medicine GLP-1 Receptor Agonist Anti-obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Huadong Medicine Recent Developments/Updates
Table 92. Huadong Medicine Competitive Strengths & Weaknesses
Table 93. Renhui Bio Basic Information, Manufacturing Base and Competitors
Table 94. Renhui Bio Major Business
Table 95. Renhui Bio GLP-1 Receptor Agonist Anti-obesity Drug Product and Services
Table 96. Renhui Bio GLP-1 Receptor Agonist Anti-obesity Drug Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Renhui Bio Recent Developments/Updates
Table 98. Renhui Bio Competitive Strengths & Weaknesses
Table 99. Global Key Players of GLP-1 Receptor Agonist Anti-obesity Drug Upstream (Raw Materials)
Table 100. Global GLP-1 Receptor Agonist Anti-obesity Drug Typical Customers
Table 101. GLP-1 Receptor Agonist Anti-obesity Drug Typical Distributors
LIST OF FIGURES
Figure 1. GLP-1 Receptor Agonist Anti-obesity Drug Picture
Figure 2. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032) & (K Units)
Figure 5. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price (2021-2032) & (US$/Unit)
Figure 6. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Region (2021-2032)
Figure 7. World GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share by Region (2021-2032)
Figure 8. North America GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032) & (K Units)
Figure 9. Europe GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032) & (K Units)
Figure 10. China GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032) & (K Units)
Figure 11. Japan GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032) & (K Units)
Figure 12. India GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032) & (K Units)
Figure 13. GLP-1 Receptor Agonist Anti-obesity Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032) & (K Units)
Figure 16. World GLP-1 Receptor Agonist Anti-obesity Drug Consumption Market Share by Region (2021-2032)
Figure 17. United States GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032) & (K Units)
Figure 18. China GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032) & (K Units)
Figure 19. Europe GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032) & (K Units)
Figure 20. Japan GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032) & (K Units)
Figure 21. South Korea GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032) & (K Units)
Figure 22. ASEAN GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032) & (K Units)
Figure 23. India GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032) & (K Units)
Figure 24. Producer Shipments of GLP-1 Receptor Agonist Anti-obesity Drug by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for GLP-1 Receptor Agonist Anti-obesity Drug Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for GLP-1 Receptor Agonist Anti-obesity Drug Markets in 2025
Figure 27. United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share 2025
Figure 31. China Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share 2025
Figure 32. Rest of World Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share 2025
Figure 33. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 34. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Type in 2025
Figure 35. Semaglutide
Figure 36. Liraglutide
Figure 37. Oral GLP-1 Agonist
Figure 38. Long-acting GLP-1 Agonist
Figure 39. Generic Or Biosimilar GLP-1
Figure 40. Next-generation GLP-1
Figure 41. Other
Figure 42. Other
Figure 43. World GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share by Type (2021-2032)
Figure 44. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Type (2021-2032)
Figure 45. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Type (2021-2032) & (US$/Unit)
Figure 46. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 47. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Dosage Form in 2025
Figure 48. Injectable
Figure 49. OralTablet
Figure 50. Pen Injector
Figure 51. Vial Or Cartridge
Figure 52. Implantable Or Depot
Figure 53. Other
Figure 54. World GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share by Dosage Form (2021-2032)
Figure 55. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Dosage Form (2021-2032)
Figure 56. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Dosage Form (2021-2032) & (US$/Unit)
Figure 57. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Indication, (USD Million), 2021 & 2025 & 2032
Figure 58. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Indication in 2025
Figure 59. Prescription Obesity Treatment
Figure 60. Diabetes With Weight Management
Figure 61. Cardiometabolic Risk Reduction
Figure 62. Adolescent Obesity
Figure 63. Other
Figure 64. World GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share by Indication (2021-2032)
Figure 65. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Indication (2021-2032)
Figure 66. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Indication (2021-2032) & (US$/Unit)
Figure 67. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 68. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Application in 2025
Figure 69. Hospital Pharmacies
Figure 70. Retail Pharmacies
Figure 71. Other
Figure 72. World GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share by Application (2021-2032)
Figure 73. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Application (2021-2032)
Figure 74. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Application (2021-2032) & (US$/Unit)
Figure 75. GLP-1 Receptor Agonist Anti-obesity Drug Industry Chain
Figure 76. GLP-1 Receptor Agonist Anti-obesity Drug Procurement Model
Figure 77. GLP-1 Receptor Agonist Anti-obesity Drug Sales Model
Figure 78. GLP-1 Receptor Agonist Anti-obesity Drug Sales Channels, Direct Sales, and Distribution
Figure 79. Methodology
Figure 80. Research Process and Data Source
Figure 1. GLP-1 Receptor Agonist Anti-obesity Drug Picture
Figure 2. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032) & (K Units)
Figure 5. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price (2021-2032) & (US$/Unit)
Figure 6. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Region (2021-2032)
Figure 7. World GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share by Region (2021-2032)
Figure 8. North America GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032) & (K Units)
Figure 9. Europe GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032) & (K Units)
Figure 10. China GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032) & (K Units)
Figure 11. Japan GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032) & (K Units)
Figure 12. India GLP-1 Receptor Agonist Anti-obesity Drug Production (2021-2032) & (K Units)
Figure 13. GLP-1 Receptor Agonist Anti-obesity Drug Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032) & (K Units)
Figure 16. World GLP-1 Receptor Agonist Anti-obesity Drug Consumption Market Share by Region (2021-2032)
Figure 17. United States GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032) & (K Units)
Figure 18. China GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032) & (K Units)
Figure 19. Europe GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032) & (K Units)
Figure 20. Japan GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032) & (K Units)
Figure 21. South Korea GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032) & (K Units)
Figure 22. ASEAN GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032) & (K Units)
Figure 23. India GLP-1 Receptor Agonist Anti-obesity Drug Consumption (2021-2032) & (K Units)
Figure 24. Producer Shipments of GLP-1 Receptor Agonist Anti-obesity Drug by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for GLP-1 Receptor Agonist Anti-obesity Drug Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for GLP-1 Receptor Agonist Anti-obesity Drug Markets in 2025
Figure 27. United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States VS China: GLP-1 Receptor Agonist Anti-obesity Drug Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 30. United States Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share 2025
Figure 31. China Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share 2025
Figure 32. Rest of World Based Manufacturers GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share 2025
Figure 33. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 34. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Type in 2025
Figure 35. Semaglutide
Figure 36. Liraglutide
Figure 37. Oral GLP-1 Agonist
Figure 38. Long-acting GLP-1 Agonist
Figure 39. Generic Or Biosimilar GLP-1
Figure 40. Next-generation GLP-1
Figure 41. Other
Figure 42. Other
Figure 43. World GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share by Type (2021-2032)
Figure 44. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Type (2021-2032)
Figure 45. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Type (2021-2032) & (US$/Unit)
Figure 46. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 47. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Dosage Form in 2025
Figure 48. Injectable
Figure 49. OralTablet
Figure 50. Pen Injector
Figure 51. Vial Or Cartridge
Figure 52. Implantable Or Depot
Figure 53. Other
Figure 54. World GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share by Dosage Form (2021-2032)
Figure 55. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Dosage Form (2021-2032)
Figure 56. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Dosage Form (2021-2032) & (US$/Unit)
Figure 57. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Indication, (USD Million), 2021 & 2025 & 2032
Figure 58. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Indication in 2025
Figure 59. Prescription Obesity Treatment
Figure 60. Diabetes With Weight Management
Figure 61. Cardiometabolic Risk Reduction
Figure 62. Adolescent Obesity
Figure 63. Other
Figure 64. World GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share by Indication (2021-2032)
Figure 65. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Indication (2021-2032)
Figure 66. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Indication (2021-2032) & (US$/Unit)
Figure 67. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 68. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Application in 2025
Figure 69. Hospital Pharmacies
Figure 70. Retail Pharmacies
Figure 71. Other
Figure 72. World GLP-1 Receptor Agonist Anti-obesity Drug Production Market Share by Application (2021-2032)
Figure 73. World GLP-1 Receptor Agonist Anti-obesity Drug Production Value Market Share by Application (2021-2032)
Figure 74. World GLP-1 Receptor Agonist Anti-obesity Drug Average Price by Application (2021-2032) & (US$/Unit)
Figure 75. GLP-1 Receptor Agonist Anti-obesity Drug Industry Chain
Figure 76. GLP-1 Receptor Agonist Anti-obesity Drug Procurement Model
Figure 77. GLP-1 Receptor Agonist Anti-obesity Drug Sales Model
Figure 78. GLP-1 Receptor Agonist Anti-obesity Drug Sales Channels, Direct Sales, and Distribution
Figure 79. Methodology
Figure 80. Research Process and Data Source
